The BIOSECURE Crack: US Quietly Drafting Rules to Keep Pharma Licensing With China Alive

Reuters reported on Sep 18, 2026 that the US Treasury is drafting rules that would preserve most pharmaceutical licensing deals with China, a significant walk-back from the BIOSECURE-era stance that had effectively federalized the boundary between US drug pipelines and Chinese innovation. Three people briefed on the process said the rules are likely to allow investment in \"promising new Chinese drugs\" so long as they are not tied to pathogens or biotechnology that could be weaponized — and that Treasury is unlikely to unveil the new framework before President Trump's Sep 24 summit with Xi Jinping.

The Reuters story lands in a market that had been pricing decoupling for two years. The BIOSECURE Act (P.L. 119-60, enacted Dec 18, 2025 as § 851 of the FY2026 NDDA) prohibits federal agencies from procuring biotechnology equipment or services from any designated \"biotechnology company of concern.\" In June2026, the Department of Defense added WuXi AppTec (and Complete Genomics) to its Section 1260H list, and WuXi AppTec lost an Aug 7, 2026 court challenge — though the DC District Court enjoined the 1260H designation on Aug 7, finding the agency's evidence \"factually deficient\" on the ownership stake used to justify it. The OMB retains a separate statutory path to designate biotech companies of concern that does not rely on the 1260H list at all, and must publish its first BCC list by Dec 18, 2026.

The reason the policy reversal matters is that the underlying licensing flow never stopped — it just moved into a smaller, faster lane. Chinese out-licensing hit a record $137.7B in 2025 per GlobalData, then ran at roughly $110B in H1 2026 alone (Reuters, Jul 13, 2026), with average deal sizes up 76% and upfront fees doubling. Headline transactions in 2026 were anchored by Western pharma: Bristol Myers Squibb signed a $15.2B alliance with Jiangsu Hengrui for 13 programs in oncology, hematology and immunology (May 12, 2026), and Pfizer signed a $10.5B collaboration with Innovent Biologics for 12 ADC oncology programs (May 28, 2026). The pipelines were already flowing; what was missing was a formal US government posture that would not pull the rug.

The Trump-Xi summit on Sep 24 in Washington sets a hard political deadline. Sources told Reuters the rules are likely to allow drug investment but not pathogen-adjacent biotech, framing the carve-out as a national-security exception rather than a blanket embrace. Treasury Secretary Bessent and PhRMA have both signaled comfort with the licensing flow, while a bipartisan group led by Reps. John Moolenaar and Debbie Dingell is pushing the BINSA bill to drag pharma into the existing COINS Act outbound-investment screening regime — a competing direction that could still pull the rules back toward restriction.

WuXi AppTec's H1 2026 results, released Aug 2, 2026, are the cleanest proof that the BIOSECURE-era \"decoupling\" never matched the ground reality. Revenue reached RMB 28.90B (up 38.9% YoY) and the backlog for Continuing Operations hit RMB 66.43B (up 25.2% YoY) — both records. Management raised full-year 2026 revenue guidance to RMB 58.5–60.5B (from RMB 51.3–53.0B), implying 35–39% Continuing-Operations growth. The BIOSECURE risk visibly showed up in the gap between operating cash and customer wins: customers and suppliers reportedly cancelled contracts and moved programs to competitors within weeks of the June 1260H designation, per the DC District Court's irreparable-harm analysis. Treasury's draft rules unwind precisely that overhang.

WuXi Biologics, the bioservices sister, reported H1 2026 revenue of RMB 11.8B (up 18.4% YoY) and a record US$25.1B total backlog as of Jun 30, 2026 (US$12.6B service backlog + US$12.4B potential milestone payments). Three-year backlog hit US$5.5B, up ~30% YoY. The company filed 68 INDs during the period and plans to lift filing capacity to 300/year by 2027. Notably, WuXi Biologics was not added to the June 2026 1260H update (unlike WuXi AppTec), so the Treasury carve-out has direct read-across to a backlog that already prices further US customer wins.

The second-order story is about the US clinical CROs whose bull case was \"China decoupling, US biotech comes home.\" Those bids were won — Charles River Laboratories returned to positive organic growth (+0.1%) in Q2 2026 for the first time since Q3 2023, and lifted full-year organic guidance to 0.0–1.0% from prior (1.5)–(0.5)%, raising non-GAAP EPS guidance to $11.15–11.45 from $10.80–11.30. But the rerating is now constrained: if US biotech can keep sourcing molecules from China, the bid for share-of-wallet at the US CROs moderates, even if total R&D spend keeps rising.

IQVIA is the cleanest second-order winner. Its R&D Solutions segment posted $2.575B in Q2 2026 revenue (+8.8% YoY) and a record $3.15B in net new bookings (+19% YoY), lifting the contracted backlog to $34.2B — both absolute backlog and bookings growth are at multi-year highs. The licensing-policy relief means more China-originated molecules enter the clinic, and IQVIA runs the trials. ICON's $23.4B backlog (+3.0% QoQ in Q2 2026) and 1.42x net book-to-bill tell the same story. The bear case for the US CROs was that biotech would just R&D in China and outsource in China; the draft rules now say they can both.

For the Chinese innovators themselves, the licensing carve-out is the most direct. Innovent Biologics is already trading on the Pfizer deal: shares rose ~10% on the May 28, 2026 announcement (CNBC), and Innovent's stock sits at HK$93.55 (Sep 11, 2026, Bloomberg), well off the HK$112.70 52-week high. The Pfizer deal's $650M upfront plus $9.85B of milestone eligibility is the single largest payment in Innovent's history; if Treasury's rules stabilize, Innovent becomes the most leveraged listed vehicle to a re-acceleration of cross-border deal flow.

Jiangsu Hengrui is a different setup — a larger incumbent ($32.6B TTM revenue per Yahoo Finance) whose H1 2026 results showed RMB 15.46B in revenue with drug-sales revenue up 1.87% YoY. The Bristol Myers Squibb $15.2B deal (announced May 12, 2026, expected to close Q3 2026) is the largest in Hengrui's history and the second mega-deal with a Western pharma in under a year (following the December 2024 GSK $12B deal). The stock at HK$45.94 (Hengrui IR page Sep 11, 2026) sits only 3.15% above its 52-week low of HK$45.08 (set Sep 2, 2026). If the Treasury rules hold, Hengrui becomes the highest-quality way to play a continued re-rating of Chinese biopharma in global pharma pipelines.

The Reuters story is explicit that \"rules are not finalized and could change\" — and there are three named live threats. First, the OMB must publish its first statutory list of \"biotechnology companies of concern\" by Dec 18, 2026 (one year after enactment of P.L. 119-60). The OMB has an independent path that does not rely on the 1260H list; WuXi AppTec's 1260H designation is currently enjoined by court order, but a clean OMB BCC designation would re-impose the BIOSECURE risk from a different statutory doorway. Second, the BINSA bill (Jun 2026, sponsored by Moolenaar and Dingell) would explicitly add pharma to the existing COINS Act outbound investment screening regime, putting drug licensing back into Treasury's review queue. Third, the Trump-Xi summit on Sep 24 will determine the political envelope — and any post-summit concession on Taiwan, fentanyl, or agriculture could be paired with a tougher biotech screen.

There is also an upstream consideration. The Aug 7, 2026 court injunction against the 1260H designation relied on the court finding that customers and suppliers had cancelled contracts and moved programs to competitors within weeks of the June 2026 designation — i.e., the commercial damage was already done even when the designation was later set aside. If Treasury's draft rules stick, WuXi AppTec has to rebuild that business pipeline while competing against the ICON and Charles River Laboratories capacity that absorbed the redirected work. Backlog conversion is the score to watch, not headline revenue.

The horizon-weighted view: in days, the Trump-Xi summit and post-summit Treasury announcement drive headline volatility. In quarters, the OMB BCC list and the BINSA bill mark the next binary policy events; investors who price only the licensing carve-out miss the BCC list risk. In years, the question is whether Chinese innovators (Innovent Biologics, Jiangsu Hengrui) and CRDMOs (WuXi AppTec, WuXi Biologics) can rebuild trust and capacity fast enough to capture the patent-cliff-driven in-licensing wave — and whether the US clinical CROs (IQVIA, ICON) can hold share-of-wallet against a reinvigorated China R&D ecosystem.